For the quarter ending 2025-09-30, AKTX made $16K in revenue. -$6,438K in net income. Net profit margin of -40237.50%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Restructuring and other costs | - | 0 | ||
| Research and development | 249 | 667 | ||
| General and administrative | 1,975 | 2,452 | ||
| Merger-related costs | - | 0 | ||
| Impairment loss on other intangible assets | 5,180 | - | ||
| Loss from operations | -7,404 | -3,119 | ||
| Other expense, net | - | 0 | ||
| Interest income | 1 | 0 | ||
| Interest expense | 121 | 50 | ||
| Gain on settlement of current liabilities | 774 | 1,190 | ||
| Loss on debt extinguishment | -967 | - | ||
| Change in fair value of warrant liabilities | 253 | 134 | ||
| Foreign currency exchange gain (loss), net | 76 | -50 | ||
| Loss on derivative liability | -100 | - | ||
| Total other income (expense), net | -84 | 1,224 | ||
| Net loss before income taxes | -7,488 | - | ||
| Benefit from deferred income taxes | -1,088 | - | ||
| Net loss | -6,400 | -1,895 | ||
| Foreign currency translation adjustment | -38 | -333 | ||
| Total other comprehensive (loss) income, net of tax | -38 | -333 | ||
| Total comprehensive loss | -6,438 | -2,228 | ||
| Net loss per share - basic | 0 | 0 | ||
| Net loss per share - diluted | 0 | 0 | ||
| Weighted-average number of ordinary shares used in computing net loss per share - basic | 65,326,236,698 | 62,943,895,665 | ||
| Weighted-average number of ordinary shares used in computing net loss per share - diluted | 65,326,236,698 | 62,943,895,665 | ||
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)